Psilocybin for Depression: Promising Results from the EPISODE Trial

Key Takeaways

The EPISODE trial is the largest German study on psilocybin for depression to date, run by the Central Institute of Mental Health in Mannheim and Charité Berlin, published in March 2026 in JAMA Psychiatry:

• 144 participants with treatment-resistant depression took part
• Fast onset of effect: After just one week, 34% of participants on 25mg psilocybin showed a response, compared with 10.4% (5mg) and 6.4% (placebo)
• A statistically clear reduction in symptoms: After six weeks, the difference from placebo was highly significant (p<0.001)
• A lasting effect: The response rate kept climbing through week 12, up to 27-34%

We'll walk through the numbers in detail.

---

What Was Studied?

Treatment-resistant depression means standard antidepressants haven't worked well enough. According to the research literature, more than 30% of people with depression don't respond satisfactorily to available medication, and up to 80% of them relapse within a year. That's exactly the group the EPISODE trial was designed for.

144 adults, most with several unsuccessful antidepressant trials behind them, took part across two psychiatric hospitals in Germany. The trial was triple-blind: neither the investigators, the participants, nor the people rating symptoms knew who received which substance.

Participants were split into three groups:

• 25mg psilocybin: the full dose
• 5mg psilocybin: a low dose
• Nicotinamide, 100mg: an active placebo that causes mild physical sensations like warmth, so participants couldn't simply tell from the absence of physical effects that they hadn't received psilocybin

Each dose was embedded in a supported psychotherapy session, with preparation beforehand and follow-up conversations afterward.

---

What Do the Results Show?

The most striking finding: the effect kicked in fast. Just one week after the first dose, the response rate under 25mg psilocybin was 34.0%, compared with 10.4% under the low dose and only 6.4% under placebo.

Time point	25mg psilocybin	5mg psilocybin	Placebo
Week 1	34.0%	10.4%	6.4%
Week 6	17.0%	12.5%	10.6%
Week 12	27-34%	–	–

This was measured using the HAMD-17: a questionnaire doctors use to check how severe a depression currently is. A doctor asks about sleep, mood, and energy and scores the answers: the lower the final score, the better the person is doing. On this scale, scores under 25mg psilocybin dropped by an average of 6.06 points after six weeks, compared to just 1.51 points under placebo, a difference of 4.60 points (95% confidence interval: -7.01 to -2.18; p<0.001). The effect held up over the entire study period: the response rate kept rising through week 12, suggesting a benefit from continued therapeutic engagement.

The study authors sum it up in their own "Meaning" statement: psilocybin, 25mg, with adjunct psychotherapy, may exert clinically meaningful antidepressant effects in treatment-resistant depression.

---

What Does This Mean for You?

Worth stating upfront: this trial studied psilocybin as a possible treatment for a clinically diagnosed, treatment-resistant depression: a medical context that's different from our retreats. We don't offer depression treatment; our retreats don't replace medical or psychotherapeutic care.

What the trial shows: psilocybin has real, promising potential for depression, especially through its fast onset of effect, which stands in clear contrast to classic antidepressants that often take weeks to work. The individual differences in the trial echo what's repeatedly described in psychedelic guidance outside clinical settings too: how an experience affects someone depends heavily on the person, the preparation, and the setting.

Lead researcher Gerhard Gründer described the range of effects like this:

"The individual differences in effect were considerable – from barely noticeable to extraordinarily positive in some patients." – Gerhard Gründer, lead researcher (translated from German)

Does This Apply to LSD Too?

The EPISODE trial tested psilocybin exclusively, not LSD. Whether LSD derivatives would show a similarly fast onset of effect hasn't been directly studied. What is interesting, though, is that psilocybin and LSD act on the same receptor (5-HT2A) and activate the same signaling pathways in the brain (TrkB, mTOR) — exactly the mechanisms also linked to fast antidepressant effects.

➡️ View the Study: Psychedelics Promote Structural and Functional Neural Plasticity

That makes it scientifically plausible that LSD derivatives could show similar effects. For depression specifically, though, this has so far only been directly tested with psilocybin.

---

Conclusion

The EPISODE trial delivers a promising picture: a fast onset of effect, a statistically clear reduction in symptoms, and an effect that held up, or even grew, over twelve weeks. For research into psilocybin for treatment-resistant depression, that's a meaningful result.

You can find the full study data, authors, and original publication in our research database:

➡️ View the Full Study Overview

More on this topic:

• Our Research Page: all scientific studies at a glance
• What Is Psilocybin?: a comparison with LSD

Note: Psychedelic retreats do not replace medical or psychotherapeutic treatment. The described effects are based on experience reports and ongoing research.